Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | CAR T-cell therapy for high-risk multiple myeloma

Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses the efficacy of chimeric antigen receptor (CAR) T-cell treatment in high-risk multiple myeloma patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Michel Delforge, MD, PhD, has participated in advisory boards for Amgen, Celgene-BMS, GSK, Janssen, Takeda and Sanofi; and has received research grants from Amgen, Celgene, Janssen, Takeda and Sanofi.